WO2005118584A3 - Saframycin analogs as therapeutic agents in the treatment of cancer - Google Patents

Saframycin analogs as therapeutic agents in the treatment of cancer Download PDF

Info

Publication number
WO2005118584A3
WO2005118584A3 PCT/US2005/018504 US2005018504W WO2005118584A3 WO 2005118584 A3 WO2005118584 A3 WO 2005118584A3 US 2005018504 W US2005018504 W US 2005018504W WO 2005118584 A3 WO2005118584 A3 WO 2005118584A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
cancer
treatment
saframycin
therapeutic agents
Prior art date
Application number
PCT/US2005/018504
Other languages
French (fr)
Other versions
WO2005118584A2 (en
Inventor
Hyunjin M Kim
Martin Sendzik
Jeffrey R Spencer
Penglie Zhang
Original Assignee
Axys Pharm Inc
Hyunjin M Kim
Martin Sendzik
Jeffrey R Spencer
Penglie Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharm Inc, Hyunjin M Kim, Martin Sendzik, Jeffrey R Spencer, Penglie Zhang filed Critical Axys Pharm Inc
Publication of WO2005118584A2 publication Critical patent/WO2005118584A2/en
Publication of WO2005118584A3 publication Critical patent/WO2005118584A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention is directed to saframcyin analogs that are useful in the treatment of cancer. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
PCT/US2005/018504 2004-05-26 2005-05-26 Saframycin analogs as therapeutic agents in the treatment of cancer WO2005118584A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57470004P 2004-05-26 2004-05-26
US60/574,700 2004-05-26

Publications (2)

Publication Number Publication Date
WO2005118584A2 WO2005118584A2 (en) 2005-12-15
WO2005118584A3 true WO2005118584A3 (en) 2006-03-23

Family

ID=35004181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/018504 WO2005118584A2 (en) 2004-05-26 2005-05-26 Saframycin analogs as therapeutic agents in the treatment of cancer

Country Status (1)

Country Link
WO (1) WO2005118584A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ554761A (en) 2004-10-29 2010-01-29 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
WO2006066183A2 (en) * 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
ES2551731T3 (en) * 2007-11-19 2015-11-23 Asahi Kasei Chemicals Corporation Process for the manufacture of isocyanates and aromatic hydroxy compounds
JOP20190254A1 (en) 2017-04-27 2019-10-27 Pharma Mar Sa Antitumoral compounds
CN107759652B (en) * 2017-08-30 2019-10-29 大连理工大学 Containing cholesteric coumarin derivatives and its synthesis and application
WO2019176732A1 (en) * 2018-03-16 2019-09-19 国立大学法人東京農工大学 Production method for tetrahydroisoquinoline ring-containing compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040477A2 (en) * 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040477A2 (en) * 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WERMUTH ET AL, PRACTICE OF MEDICINAL CHEMISTRY, 1996, pages 203 - 237, XP002190259 *

Also Published As

Publication number Publication date
WO2005118584A2 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
UA86614C2 (en) Compound having kinase ingibitor activity, pharmaceutical composition containing thereof and use thereof for the preparation of medicine
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
IL180677A0 (en) Compounds, compositions and methods for treatment of hyperproliferative diseases, such as cancer
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
MX2009006704A (en) New compounds.
WO2006058868A8 (en) Substituted pteridines for treating inflammatory diseases
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
TW200531689A (en) Therapeutic agents
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
IL187382A0 (en) Bicyclic derivatives as modulators of ion channels
WO2006138528A3 (en) Tricyclic opioid modulators
TW200628473A (en) Novel heterocycles
WO2005103010A3 (en) Pyrazole derivatives useful for the treatment of cancer
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
WO2005118584A3 (en) Saframycin analogs as therapeutic agents in the treatment of cancer
MX2010003269A (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase.
WO2006074388A3 (en) TRICYCLIC δ-OPIOID MODULATORS
WO2006066183A3 (en) Novel saframycin analogs as therapeutic agents
WO2005055939A3 (en) Vinca derivatives
IL183893A0 (en) Pharmaceutical compositions for the treatment of cellulite

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase